Katharina Boehm1,2, Paolo Dell'Oglio3,4, Zhe Tian3,5, Umberto Capitanio4, Felix K H Chun6, Derya Tilki7,6, Axel Haferkamp8, Fred Saad9, Francesco Montorsi4, Markus Graefen7, Pierre I Karakiewicz3,9. 1. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada. katharina.boehm@unimedizin-mainz.de. 2. Department of Urology, University Medical Center, Johannes Gutenberg University, Mainz, Germany. katharina.boehm@unimedizin-mainz.de. 3. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada. 4. Unit of Urology, Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. 5. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada. 6. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 7. Martini-Clinic, Prostate Cancer Centre, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 8. Department of Urology, University Medical Center, Johannes Gutenberg University, Mainz, Germany. 9. Department of Urology, University of Montreal Health Center, Montreal, Canada.
Abstract
INTRODUCTION: Age and Charlson comorbidity index (CCI) affect life expectancy (LE) and other-cause mortality (OCM) in non-metastatic prostate cancer (nmPCa) patients. We examined their ability to predict OCM in individuals treated with radical prostatectomy (RP), brachytherapy (BT), external beam radiation (EBRT) androgen deprivation (ADT) or observation. We postulated that these variables are not sufficient to explain OCM and LE patterns according to different treatment types. PATIENTS AND METHODS: We relied on the SEER-Medicare database from 1991 to 2009. Overall, 283,125 patients with non-metastatic prostate cancer aged ≥66 years were treated with RP (15.5%), BT (13.9%), EBRT (21.4%), ADT alone (16.3%) or observation (32.8%). Cumulative incidence of OCM and LE was stratified by treatment type and adjusted for age and CCI. Competing risks regression was also used. RESULTS: OCM rates vary according to treatment, despite age and CCI adjustment. In RP or BT patients, LE exceeds 10 years, regardless of age and CCI. Conversely, a 10-year LE is not reached by patients >74 years treated with observation or ADT. In OCM competing risks regression, age, CCI and treatment type achieved independent predictor status (all p < 0.001). CONCLUSION: In patients with nmPCa, neither age nor CCI can accurately estimate OCM or LE in excess of 10 years. Primary treatment assignment is a strong determinant of OCM and LE, where RP and BT patients enjoy better OCM and LE rates than observation ADT or EBRT patients. In consequence, better clinical tools are needed to accurately assess OCM and LE in those settings.
INTRODUCTION: Age and Charlson comorbidity index (CCI) affect life expectancy (LE) and other-cause mortality (OCM) in non-metastatic prostate cancer (nmPCa) patients. We examined their ability to predict OCM in individuals treated with radical prostatectomy (RP), brachytherapy (BT), external beam radiation (EBRT) androgen deprivation (ADT) or observation. We postulated that these variables are not sufficient to explain OCM and LE patterns according to different treatment types. PATIENTS AND METHODS: We relied on the SEER-Medicare database from 1991 to 2009. Overall, 283,125 patients with non-metastatic prostate cancer aged ≥66 years were treated with RP (15.5%), BT (13.9%), EBRT (21.4%), ADT alone (16.3%) or observation (32.8%). Cumulative incidence of OCM and LE was stratified by treatment type and adjusted for age and CCI. Competing risks regression was also used. RESULTS: OCM rates vary according to treatment, despite age and CCI adjustment. In RP or BT patients, LE exceeds 10 years, regardless of age and CCI. Conversely, a 10-year LE is not reached by patients >74 years treated with observation or ADT. In OCM competing risks regression, age, CCI and treatment type achieved independent predictor status (all p < 0.001). CONCLUSION: In patients with nmPCa, neither age nor CCI can accurately estimate OCM or LE in excess of 10 years. Primary treatment assignment is a strong determinant of OCM and LE, where RP and BT patients enjoy better OCM and LE rates than observation ADT or EBRTpatients. In consequence, better clinical tools are needed to accurately assess OCM and LE in those settings.
Authors: H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman Journal: J Urol Date: 2013-05-06 Impact factor: 7.450
Authors: Patti A Groome; Susan L Rohland; D Robert Siemens; Michael D Brundage; Jeremy Heaton; William J Mackillop Journal: Cancer Date: 2011-02-24 Impact factor: 6.860
Authors: Maxine Sun; Firas Abdollah; Daniel Liberman; Al'a Abdo; Rodolphe Thuret; Zhe Tian; Shahrokh F Shariat; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: Cancer Date: 2011-03-08 Impact factor: 6.860
Authors: Margaret G Stineman; Dawei Xie; Qiang Pan; Jibby E Kurichi; Zi Zhang; Debra Saliba; John T Henry-Sánchez; Joel Streim Journal: J Am Geriatr Soc Date: 2012-02-21 Impact factor: 5.562
Authors: Jochen Walz; Felix K-H Chun; Eric A Klein; Alwyn Reuther; Fred Saad; Markus Graefen; Hartwig Huland; Pierre I Karakiewicz Journal: J Urol Date: 2008-12-13 Impact factor: 7.450
Authors: Timothy J Daskivich; Kang-Hsien Fan; Tatsuki Koyama; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Janet L Stanford; Antoinette M Stroup; Mark S Litwin; David F Penson Journal: Ann Intern Med Date: 2013-05-21 Impact factor: 25.391
Authors: Ryan M Fiano; Gregory S Merrick; Kim E Innes; Malcolm D Mattes; Traci J LeMasters; Chan Shen; Usha Sambamoorthi Journal: Cancer Med Date: 2020-07-06 Impact factor: 4.452